MediGene news from FierceBiotech
NewsMediGene sells European rights to Oracea
MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones. Read more...
Unexpected death brings MediGene Phase I to a halt
MediGene AG placed a clinical hold on the trial of an experimental therapy for rheumatoid arthritis after a paid subject in the Phase I study - a healthy father of three -- died unexpectedly in Read more...
Pfizer rumored to be eyeing MediGene buyout
Rumors are swirling that Pfizer is looking to take over the German biotech Read more...
| Press ReleasesPRESS RELEASE: MediGene Raises € 15,6 Million in Private Placement with Santo Holding GmbH MediGene Raises € 15,6 Million in Private Placement with Santo Holding GmbH Martinsried/Munich, Germany – September 10, 2007. The biotechnology company MediGene announces that Santo Holding Read more... |
Get more MediGene coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets